One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Homologous recombination deficiency testing in first-line ovarian cancer
K.N.Moore1A.du Bois2
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
P.Tarantino1234H.J.Burstein34N.U.Lin34I.E.Krop34E.P.Winer34S.J.Schnitt345E.P.Hamilton6S.A.Hurvitz7H.S.Rugo8G.Curigliano12S.M.Tolaney34
Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape
Anishka A.D’souza1VarshaTulpule1Peter D.Zang12David I.Quinn1
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T.Powles1J.Bellmunt2E.Comperat3M.De Santis4R.Huddart5Y.Loriot6A.Necchi7B.P.Valderrama8A.Ravaud910S.F.Shariat11B.Szabados112M.S.van der Heijden13S.Gillessen14ESMO Guidelines Committee
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
P.J.Hayden1†C.Roddie23†P.Bader4G.W.Basak5H.Bonig6C.Bonini7C.Chabannon8F.Ciceri9S.Corbacioglu10R.Ellard11F.Sanchez-Guijo12U.Jäger13M.Hildebrandt14M.Hudecek15M.J.Kersten16U.Köhl1718J.Kuball19S.Mielke20…I.Yakoub-Agha35
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
I.Vergote1A.González-MartÃn23I.Ray-Coquard4P.Harter5N.Colombo6P.Pujol7D.Lorusso8M.R.Mirza9B.Brasiuniene10R.Madry11J.D.Brenton12M.G.E.M.Ausems13R.Büttner14D.Lambrechts15
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
S.Horwitz1O.A.O'Connor2B.Pro3L.Trümper4S.Iyer5R.Advani6N.L.Bartlett7J.H.Christensen8F.Morschhauser9E.Domingo-Domenech10G.Rossi11W.S.Kim12T.Feldman13T.Menne14D.Belada15�.Illés16K.Tobinai17K.Tsukasaki18…T.Illidge28
Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3Â trial
H.S.Han1B.K.Arun2B.Kaufman3H.Wildiers4M.Friedlander5J.P.Ayoub6S.L.Puhalla7B.A.Bach8M.G.Kundu8†N.Khandelwal8D.Feng8S.Bhattacharya8‡D.Maag8C.K.Ratajczak8V.Diéras910
Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial
J.M.N.Lopes Cardozo12D.Byng3C.A.Drukker4M.K.Schmidt5M.A.Binuya56L.J.van ’t Veer7F.Cardoso8M.Piccart9C.H.Smorenburg10C.Poncet2E.J.T.Rutgers1
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
G.Curigliano1V.Mueller2V.Borges3E.Hamilton4S.Hurvitz5S.Loi6R.Murthy7A.Okines8E.Paplomata9†D.Cameron10L.A.Carey11K.Gelmon12G.N.Hortobagyi7I.Krop13S.Loibl14M.Pegram15D.Slamon5J.Ramos16…E.Winer13
European cancer mortality predictions for the year 2022 with focus on ovarian cancer
M.Dalmartello1C.La Vecchia1P.Bertuccio1P.Boffetta23F.Levi4E.Negri135M.Malvezzi1
COVID-19 vaccination and breakthrough infections in patients with cancer
A.L.Schmidt1†C.Labaki1†C.-Y.Hsu2†Z.Bakouny1†N.Balanchivadze3S.A.Berg4S.Blau56A.Daher7T.El Zarif1C.R.Friese8E.A.Griffiths9J.E.Hawley1011B.Hayes-Lattin12V.Karivedu13T.Latif14B.H.Mavromatis15R.R.McKay16G.Nagaraj17…J.L.Warner
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
F.Poggio1M.Tagliamento23M.Ceppi4M.Bruzzone4B.Conte12P.Fregatti56K.Punie7E.de Azambuja8L.Del Mastro29M.Lambertini210
Selecting the right chemotherapy in first-line advanced squamous cell carcinoma of the anus
M.Ducreux1S.Kim2C.Borg2
Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer
V.Di Noia1F.Pimpinelli2D.Renna1V.Barberi3R.Pellini4A.Morrone5D.Giannarelli6F.Cognetti13
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
F.Nelli1A.Fabbri1A.Onorato1D.Giannarelli2M.A.Silvestri3G.Pessina4J.R.Giron Berrios1A.Virtuoso1E.Marrucci1M.Schirripa1M.Mazzotta1V.Panichi3P.Cercola4C.Signorelli1M.G.Chilelli1F.Primi1E.M.Ruggeri1
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel�: [Annals of Oncology 28 (2017) 2768-2772]
U.A.Nitz12O.Gluz123M.Christgen4E.-M.Grischke5D.Augustin6S.Kuemmel7M.Braun8J.Potenberg9A.Kohls10K.Krauss11A.Stefek12C.Schumacher13H.Forstbauer14T.Reimer15H.Fischer16C.Liedtke1718R.Wuerstlein19J.Schumacher20…N.Harbeck119
Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria�: [Annals of Oncology 32 (2021) 950-953]
J.J.Gao1D.Krol2P.Narayan2F.Cardoso3M.M.Regan4M.P.Goetz5S.A.Hurvitz6L.Mauro7C.Hodgdon8C.P.Miller2B.Booth2E.Bloomquist2G.Ison2C.Osgood2V.Bhatnagar1L.Fashoyin-Aje12R.Pazdur12L.Amiri-Kordestani2J.A.Beaver12
1P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)
B.Gao1Z.Ma2X.Yu3D.Huang4J.Zhao5D.Day6A.L.Body6Q.Zhou7Q.Chu8H.Pan9J.Cui10H.Li11J.Sun11J.Zhang11C.Fei11Y-L.Wu12
2P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
Q.Zhou1X.Yu2B.Gao3Z.Ma4Q.Chu5D.Huang6J.Zhao7D.Day8A.L.Body8H.Pan9J.Cui10H.Li11J.Sun11J.Zhang11C.Fei11Y-L.Wu12
3P Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)
S.Pradhan1Y.J.Kim2J.Park3S-Y.Jeong3S.S.Koh2K.D.Mandakhalikar1J.Kim1L.Jaison1
4P Antitumor efficacy of integrin αVβ3 antibody conjugated ZnO nanocarrier-based drug delivery system to target breast carcinoma
K.VimalaS.Kannan
5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase
E.Fontana1E.Lee2E.Rosen3D.Spigel4M.Højgaard5S.Lheureux6N.B.Mettu7L.Carter8R.Plummer9P.Manley6D.Ulanet6V.Rimkunas6I.M.Silverman6J.O'Connell6R.McDougall6M.Wainszelbaum6Y.Xu6M.Koehler6…T.A.Yap10
6MO Translational relevance of the combined treatment PARP inhibitors and AsiDNA in homologous recombination proficient tumors
W.Jdey1V.Trochon-Joseph1C.Doizelet1V.Hayes1A.Cohendet1M-C.Lienafa1C.Zandanel1O.De Beaumont1J.Miara2
7MO WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in small cell lung cancer
T.Sen
8P Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer
S.Lheureux1E.Rosen2E.Lee3D.Spigel4M.Højgaard5E.Fontana4N.B.Mettu6L.Carter7S.Patel1R.Papp1S.May1P.Nejad1D.Ulanet1M.Wainszelbaum1P.Manley1M.Koehler1A.J.Fretland1R.Plummer8T.A.Yap9
9P Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase
E.Lee1T.A.Yap2E.Fontana3E.Rosen4D.Spigel3S.Lheureux5N.B.Mettu6L.Carter7R.Plummer8S.Patel5R.McDougall5R.Papp5S.May5P.Nejad5D.Ulanet5M.Wainszelbaum5P.Manley5M.Koehler5…M.Højgaard9
10P SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer
Y.Zhu1X.Chen2Q.Zhang2J.Zeng2H.Xiao1L.Yu2
11P Novel HDAC6 inhibitors show anti-lymphoma activity alone and in combination with venetoclax and copanlisib
A.A.Mensah1G.Sartori1C.Falzarano1W.Tueckmantel2A.Kozikowski2F.Bertoni1
12P Circulating tumor DNA as early marker of response to treatment in stage IV gastrointestinal cancer
P.Kirchweger1A.Kupferthaler2J.Burghofer3G.Webersinke3E.Jukic4S.Schwendinger4R.Függer5M.Biebl5H.Wundsam5H.Rumpold1
13P Transcriptional profiling of FET-rearranged sarcomas in response to SP-2577
G.Rask1E.Theisen1A.Duncan2D.Santiesteban2
14P A novel small molecule METTL3 inhibitor exerts promising antitumor effects on oral squamous cell carcinoma
P.Arumugam1V.P.Jayaseelan2
15P STELLAR-001: A phase I study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors
J.Bennouna1Y.Touchefeu2F.Ghiringhelli3N.Isambert3F.Barlesi4P.Tomasini5P.Cassier6J.Edeline7S.M.Le Sourd7D.Tosi8A.W.Tolcher9T.Marron10D.B.Marie11J.Viotti11A.Boyer Chammard11P.Martin Romano12C.Massard12
16P Checkpoint modification of BTLA-HVEM-LIGHT signaling by HSV-1 glycoprotein D (gD) improves vaccine-induced CD8+ T cell responses in pre-clinical cancer models
A.Luber1X.Zhou2Z.Xiang2W.Giles-Davis2C.Magowan1H.C.Ertl2
17P Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using tri-specific engagers
J.S.Miller1M.Felices2D.A.Vallera3B.Ettestad2C.Hallstrom2B.Kodal2D.A.Todhunter3U.S.Arvindam2S.K.Phung2Q.Kile2G.Berk4P.R.Kennedy2
18P Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma
Y-H.Yang1A.Meerveld-Eggink2A.Bex3F.Jackson-Spence1K.S.Rallis1P.R.Brian1J.Choy1C.C.Sng1P.Adeniran1J.Amin1S.Galope1N.Anderson1S.Fernandezgomez1T.B.Powles1B.E.Szabados1
19P Tumor retargeting universal chimeric antigen receptor T cell (TRUE-CAR T) therapy in solid tumors
F.MengZ.SunB.Liu
20P Immuno-modulating effects of hyperthermia on PD-L1 and NLRC5 in ovarian cancer
M.Fezza1G.Hilal1R.Tahtouh1D.Atallah2
21P Transcriptomic mapping of integrins and immune activation in high-grade serous ovarian cancer
K.I.Rojas Laimito1A.Ocana Fernandez2M.V.Villena3J.L.Gonzalez Larriba4J.Puente Vásquez4M.J.Rubio5H.GarcÃa-MartÃnez6J.Garcia-Donas7L.Manso Sánchez8
22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases
J.Tobias1M.Drinić1S.Högler2A.Schmid1E.Garner-Spitzer1L.Kenner3M.Kundi4C.C.Zielinski5U.Wiedermann1
23P Engineered chemotherapy resistant γδ T-cells with combinatorial chemotherapies can enhance tumor cell immunogenicity and killing
K.M.Rochlin1A.Jones2L.Ding1L.Lamb1A.Hjelmeland2
24P Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model
K.Briggs1G.Corriea1A.Tsai2M.Zhang3M.R.Tonini1E.W.Wilker3C.B.Davis2K.M.Cottrell4J.P.Maxwell4A.Huang5
25P Impact of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma (the MEMOIR study): A propensity score-matched analysis
D.C.Qian1T.Kleber1B.Brammer1K.M.Xu1J.M.Switchenko2J.R.Janopaul-Naylor1J.Zhong1M.L.Yushak3R.D.Harvey3C.M.Paulos4D.H.Lawson3M.K.Khan1R.R.Kudchadkar3Z.S.Buchwald1
26MO Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
S.Sun1A.Prelaj2C.Baik3X.Le4M.Garassino5M.Wollner6E.Haura7Z.Piotrowska8M.Socinski9L.Dreiling10G.Bhat11F.Lebel12R.Cornelissen13
27MO BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models
M.C.Lucas1M.Merchant2M.O'Connor3S.Smith4A.Trombino4W-Y.Zhang5J.Simon2S.Eathiraj2N.Waters2E.Buck6
28P Discovery of potent PROTAC degraders of KRASG12C based on a reversible non-covalent KRAS binder
Z.ZhangW.ZhaiH.ChenL.WangD.Liu
29P LIBRETTO-321, a phase II study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)
X.Zheng1Q.Ji2Y.Sun3M.Ge4B.Zhang5Y.Cheng6S.Lei7F.Shi8W.Zhang9M.Gao1
30P Comparative biochemical and cellular profiling of kinase inhibitors approved for clinical use from 2018 to 2020
J.Kooijman1W.Van Riel1M.Prinsen2J.Dylus1Y.Grobben1J.De Roos1J.Melis1T.De Bitter1Y.Narumi3Y.Kawase3N.Willemsen-Seegers1G.Zaman1
31P Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion: Study design and first results of the REALTRK registry
C.Vannier1A.Völkel2U.M.Martens3T.Decker4G.Köchling5S.Lange6E.Von der Heyde7T-O.Emde8A.Wortmann9R.Grunewald10M.Frank11B.Niemeier12M.Flum1B.Kasenda1
32P Anlotinib enhances the antitumor activity of high-dose irradiation combined with anti-PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer
M.Yuan1Y.Zhai1Z.Hui2
33P Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK 4/6 inhibitor) in preclinical colorectal cancer (CRC) models
R.Aslam1S.Toomey2B.Hennessy3
34P Efficacy and toxicity analysis of imatinib in newly diagnosed patients of chronic myeloid leukaemia: 18-years’ experience at a single large-volume centre
R.Yadav1S.Parikh1H.Panchal1A.Patel1A.Garg1K.Shah1P.Basu1V.C.Patel2S.R.Ganta1S.Ravichandran1D.Banerjee1
35P NSCLC: Real-world data analysis from a chain of oncology centres in Western India
A.A.Shivchhand1A.Joshi2U.Maheshwari2V.Maniar2K.Joshi2P.Kalaskar3S.Sheth3P.Kendre2R.Korgavkar2D.Morzaria2C.Pethe4S.Dhande4M.Mekha5D.Rane2S.Jagiasi2
36P A point mutation replacing cysteine with arginine at position 382 (C382R) in the transmembrane domain of FGFR2 leads to response to FGF2-inhibitor pemigatinib in chemo-refractory intrahepatic cholangiocarcinoma
L.C.Hempel1C.Lapa2A.Gaumann3J.Veloso de Oliveira4J.Scheiber5P.Philipp6C.Oyarzun7S.Wesarg7S.Robert8D.Hempel9
37P Retrospective analysis of real-world data to evaluate actionability of a large molecular profiling panel in solid tumors (REALM study)
K.Leroy1C.Audigier Valette2S.Galoin3A.Civet4A.Italiano5
38P New tetraamine compounds targeting BCSCs from chemoresistant basal-like TNBC subtypes
A.Sevillano Chapartegui1M.Rodriguez2M.Costas2X.Ribas2S.Ruiz-Martinez1T.Puig1
39P OLIMPIA dataset: Radiomics to predict outcomes in EGFR-mutant non-small cell lung cancer
G.Pérez1J.N.Minatta2M.Aineseder3C.Mosquera1S.E.Benitez1
40P Real-world clinical genomic analysis of patients with BRAF mutated cancers identifies BRAF class II and III as a population of unmet medical need
P.Severson1W.Kellner2A.Franovic1N.Miller1E.Murphy1E.S.Martin1R.Williams3
41P The SARS-CoV-2 vaccine and enrollment of patients with cancer in phase I trials: The experience at Institute Gustave Roussy
L.Belcaid1C.Baldini2A.Laparra2
42P BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity
H.A.Lane1E.Zanini1N.Forster-Gross1K.Litherland2F.Bachmann1L.Bury1N.Willemsem-Seegers3J.De Man3D.Vu-Pham3W.Van Riel3G.Zaman3R.Buijsman3A.Groner1M.Roceri1K.Burger1P.McSheehy1L.Kellenberger1
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
T.A.Leal1D.Berz2I.Rybkin3W.T.Iams4D.Bruno5C.Blakely6A.Spira7M.Patel8D.M.Waterhouse9D.Richards10A.Pham11R.Jotte12E.B.Garon13D.S.Hong14R.Shazer15X.Yan16L.Latven17K.He18
44P A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors
T.Yun1S.J.Shin2D-W.Kim3C.H.Yun4S.Heo5B.Hyun5Y.S.Kim6J.S.Kim7Y.W.Moon8
45P Alofanib in subsequent therapy of advanced gastric cancer: Final results from the phase Ib clinical trial
L.Y.Vladimirova1V.Kurakin2N.Besova3G.Statsenko2A.Mochalova4N.Trenina2E.Artamonova3K.Novoselova5T.Titova3N.A.Abramova5E.Obarevich3A.Kashanova4M.Suetina4I.Agranov6S.Iugai7G.Raskin8V.Kazey9I.Rykov10…I.Tsimafeyeu11
46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma
K.V.Lawson1K.E.Sivick Gauthier2D.Piovesan2A.Mailyan1G.Mata1J.T.A.Fournier1K.Yu1S.Liu3F.Soriano3L.Jin4E.Ginn4P.G.Schweickert2C.A.Meleza3A.Pham5L.Seitz6K.Liao7E.Paterson8P.Foster8…M.Leleti1
47P Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial Finder
S.C.A.Rae1E.Plummer1L.Fitzgerald1L.Hogarth1A.Bridgewood1L.Brown-Schofield1J.Graham1Y.Drew1N.Haris1S.Bashir1R.Plummer1A.Greystoke2
48P cERBB-2/HER-2neu overexpression and its prognostic significance in uterine carcinosarcoma
H.S.Semiz1E.E.Pala2B.Can3E.Atağ4H.Güngör4H.Ellidokuz5M.Sancı3
49P Antitumor effects of cationic dendritic molecules and their complexes with microRNA in glioblastoma stem-like cells
N.Knauer1E.Pashkina1V.Kozlov1R.Gomez2A-M.Caminade3U.Kahlert4E.Apartsin3
50P Targeting the renin-angiotensin system in gastric cancer therapeutics
S.Chimed
51P Mitochondrial pro-apoptotic properties of isolated compounds from two soft corals of Persian Gulf
A.Yegdaneh
52P Novel inhibitors of androgen receptor with antiproliferative potency against hormone-sensitive and hormone-resistant breast cancer cells
A.M.Scherbakov1S.Krymov2D.Sorokin1D.I.Salnikova1A.Shchekotikhin2
53P Assessing the reporting quality of early phase dose-finding trials
C.Yap1O.Solovyeva2Z.Yin2J.Martin3T.Manickavasagar3C.Weir4S.Lee5M.Dimairo6R.Liu7A.Kightley8J.S.de Bono9
54P Targeted treatment options for childhood hepatoblastoma using high-throughput drug screening
R.Nousiainen1K.Eloranta1A.Hassinen2J.Saarela2S.Cairo3V.Pietiäinen2M.Heikinheimo1M.Pihlajoki1
55P Potential benefits of extensive genomic analysis in patients with KRAS mutated solid tumors: Concurrent alterations and potential targets
I.C.Jacobsen1I.Spanggaard1M.Hoejgaard2L.Belcaid1C.Qvortrup2C.W.Yde3A.Y.Schmidt3F.C.Nielsen3G.L.Willemoe4M.S.Dam5U.Lassen2K.S.Rohrberg2
56P An institutional study evaluating the benefit of blood NGS over conventional hotspot molecular genetic testing in metastatic adenocarcinoma lung
R.Ashwath
